A Study to Investigate Effect of Clarithromycin, a Strong CYP3A4 Inhibitor, on Brensocatib Pharmacokinetics in Healthy Participants
Trial Summary
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial organizers or your doctor.
What is the purpose of this trial?
This trial aims to see how taking clarithromycin changes the way brensocatib is processed in healthy people. Brensocatib is currently being developed for the treatment of bronchiectasis and other chronic inflammatory diseases.
Eligibility Criteria
Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a single oral dose of brensocatib on Days 1 and 13, and oral doses of clarithromycin twice daily from Days 8 to 19. On Day 13, brensocatib is coadministered with clarithromycin.
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Brensocatib
- Clarithromycin
Find a Clinic Near You
Who Is Running the Clinical Trial?
Insmed Incorporated
Lead Sponsor